Transpoc Inc

Nonprofit profile at a glance

EIN
462805281
IRS 990 coverage
2014–2014
Forms available
Form 990 2014
Location
Cambridge, MA, USA
Phone
6175255004
Rating confidence
Limited
Sector
Medical Disciplines Research

Official website

Reported finances

Revenue
$-2,207
Expenses
$909,810
Assets
$80,849
Liabilities
$1,263,175

Source: IRS Form 990. Selected filing: tax year 2014. Amounts in USD.

Leadership & pay

5 people listed

Executive titles in this filing

  • MARKUS WARMUTH (DIRECTOR, PRESIDENT)

People named in this filing

  • STEPHEN FRIEND (DIRECTOR)
  • JOSH SOMMER (DIRECTOR)
  • MARKUS WARMUTH (DIRECTOR, PRESIDENT)

Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.

Source: IRS Form 990. Selected filing: tax year 2014. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

Transpoc cultivates open collaboration among a wide range of oncology drug discovery organizations, including academic and medical institutions, emerging drug discovery companies, large biopharmaceutical corporations and disease-based foundations.

What it reported doing in 2014

Transpoc is a not-for-profit scientific research organization that will provide its sponsors with unprecedented access to data and large-scale technologies to accelerate the discovery of breakthrough cancer medicines. Transpoc cultivates open collaboration among a wide range of oncology drug discovery organizations, including academic and medical institutions, emerging drug discovery companies, large biopharmaceutical corporations and disease-based foundations.transpoc's purpose: perform scientific research that enables the oncology field to develop and deliver more effective personalized therapies to patients. To that end, transpoc is building sharable, large-scale, integrated and capital-efficient translational oncology platforms and bioinformatics capabilities that enable greater clinical proof-of-concept success in the development of new cancer therapies.genetic diversity in human cancers presents a significant challenge for those developing new treatments. Active collaboration provides the best potential to transform this challenge into opportunity.the success of next-generation precision cancer medicine is dependent on appropriately defining patient populations and matching them to the 'right' treatments for their specific cancers. Genetically characterized cancer cell lines and patient-derived xenograft models are emerging as promising platforms to drive the development of the 'right' treatment options. While these technologies already exist, it is beyond the reach of most companies to develop and maintain them in-house at a scale that is cost effective and scientifically relevant.to address these scale and accessibility issues, transpoc's research platforms offer access to shared global technology and translational research resources. This collaborative approach enables all participants, regardless of size, to access technologies critical for successful precision medicine development in a precompetitive space.

Operating model

Revenue model
No positive adjusted resources. The filing reports no positive adjusted operating resources.
Distribution model
Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.

The verdict

- The available evidence is not sufficient to produce an overall rating for this filing. This is not a warning sign.

Rating breakdown

  • Financial Efficiency: 52
  • Transparency & Controls: 50
  • Accountability: 81
  • Sustainability: 10
  • Growth: NotEnoughData

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: Limited
  • Program expense ratio: 67.9%; rating input score 68
  • Fundraising efficiency: $0 raised per $1 spent on fundraising; rating input score 3; 3rd percentile among comparable filings

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 62nd percentile among comparable filings
  • Pay-setting controls: Limited
  • Foreign activity oversight: Scored; rating input score 0
  • Grant itemization coverage: Scored; rating input score 0
  • Major donor itemization: Limited
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 66.7%; rating input score 67; 22nd percentile among comparable filings
  • Governance controls: 7 of 7 controls in place; rating input score 100
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Pass
    • Document-retention policy: Pass
    • CEO compensation review process: NotApplicable
    • Other executive compensation review process: NotApplicable
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Pass
    • Independent financial-statement audit: Pass

Sustainability

  • Operating margin: -41,323.8%; rating input score 1; 1st percentile among comparable filings
  • Total-asset coverage ratio: 0.09; rating input score 7; 7th percentile among comparable filings
  • Liabilities to assets ratio: 15.62; rating input score 1; 1st percentile among comparable filings
  • Officer compensation ratio: 0%; rating input score 62; 62nd percentile among comparable filings

Growth

  • Program expense growth: Limited
  • Revenue growth: Limited
  • Asset growth: Limited

Details

  • Where the money goes: 67.9% of spending went to programs
  • Governance: 2 of 3 board members independent · 7 of 7 filing controls reported
  • Programs: 1 filed program accomplishment · $618K in reported program spending
  • Leadership: top reported pay $0 · 5 people listed
  • Highest-paid contractors: 2 contractors listed · $520K reported
  • Consistency: 22 of 22 current checks pass
  • Schedules: 6 filed schedules · includes foreign activity
  • Contacts: How to reach this organization
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • High — Financial Efficiency: Fundraising efficiency scored 3/100.
  • High — Transparency & Controls: Foreign activity oversight scored 0/100.
  • High — Transparency & Controls: Grant itemization coverage scored 0/100.
  • High — Sustainability: Operating margin scored 1/100.
  • High — Sustainability: Total-asset coverage ratio scored 7/100.
  • High — Sustainability: Liabilities to assets ratio scored 1/100.